Key result
Low serum albumin is linked to ~252% greater MACE risk, modified by total cholesterol.
Why the study?
It was unknown whether the risk of poor prognosis in patients with coronary artery disease is jointly affected by total cholesterol and baseline serum albumin.
Does baseline serum albumin and total cholesterol interactively affect the risk of major adverse cardiac events in patients with stable coronary artery disease undergoing PCI?
Cohort (n=204)
No
Does baseline serum albumin and total cholesterol interactively affect the risk of major adverse cardiac events in patients with stable coronary artery disease undergoing PCI?
Hazard Ratio: 3.52 (95% CI 1.3–9.54)
Absolute Event Rate: 24.7% vs 5.3%
p-value: p=0.0133
Baseline serum albumin and total cholesterol interactively affect the risk of major adverse cardiac events in patients with stable coronary artery disease undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Combined cholesterol-albumin assessment may refine MACE risk stratification in stable CAD; hypothesis-generating and requires prospective validation.
Yao et al. (2022) conducted a cohort in stable coronary artery disease (n=204). Low baseline serum albumin (< 4 g/dL) vs. High baseline serum albumin (≥ 4 g/dL) was evaluated on Major adverse cardiac events (all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke) (HR 3.52, 95% CI 1.30-9.54, p=0.0133). Lower baseline serum albumin was associated with a significantly higher risk of major adverse cardiac events (HR 3.52), and this relationship was significantly modified by total cholesterol levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: